Repligen reported second-quarter 2026 revenue of $204.1 million, up 12% year-over-year (13% organic), and GAAP diluted EPS of $0.09 alongside adjusted diluted EPS of $0.54. GAAP income from operations was $14.0 million while adjusted income from operations was $34.0 million. The company raised full-year 2026 organic revenue growth guidance to 10.5%–13.5% and adjusted diluted EPS guidance to $2.03–$2.09.
Financial Highlights
- Total reported revenue: $204.1 million for Q2 2026 (vs. $182.4 million in Q2 2025); reported growth 12%, organic growth 13%.
- Gross margin (GAAP) for Q2 2026: 53.9% (Q2 2025: 51.0%).
- Income from operations (GAAP): $14.0 million for Q2 2026; adjusted income from operations (non-GAAP): $34.0 million.
- Net income (GAAP): $5.0 million for Q2 2026; diluted EPS (GAAP): $0.09. Adjusted net income (non-GAAP): $30.8 million; adjusted diluted EPS (non-GAAP): $0.54.
- Cash, cash equivalents and marketable securities: $810 million at June 30, 2026; total assets: $2.950 billion and total stockholders’ equity: $2.112 billion.
Business Highlights
- Announced a definitive agreement to acquire BioLife Solutions to enhance cell therapy capabilities and add a consumables platform with recurring revenue and commercial-stage exposure.
- Opened a new Repligen Training & Innovation Center at the OPUS® Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands to support training and innovation activities.
- Published the 2025 Sustainability Report titled “Driving Sustainable Growth Together,” outlining initiatives on responsible business practices, workforce development, community engagement and governance.
- Reported continued order momentum and portfolio diversification driving sequential acceleration and market outperformance, supporting an increase in full-year guidance.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.